Acción ARROWHEAD RESEARCH CORP
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Arrowhead Research Corp Nasdaq

Acciones

US0427972098

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial
Sector Update: Health Care Stocks Advance Monday Afternoon
Arrowhead Says Potential Obesity Treatment Shows 'Promising' Preclinical Results -- Shares Rise
Arrowhead Pharmaceuticals : American Diabetes Association (ADA) 84th Scientific Sessions View Presentation
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals : TIDES USA 2024 TIDES 2024 AdiposeTIDES 2024 ARO-SOD1
Arrowhead Pharmaceuticals : 2024 Second Quarter Results Prepared Remarks
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ARWR
  4. Acción
  5. Noticias Arrowhead Research Corp
  6. Otros idiomas